TECENTRIQ
Tecentriq, is a monoclonal antibody medication used to treat, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC),
small cell lung cancer (SCLC), and mUC (bladder cancer). Since 2017 I’ve lead the creative teams to successfully launch 5 indications, including the most recent in 2021, for the first and only cancer immunotherapy approved for the treatment of NSCLC in the adjuvant setting. The multi-channel “To Be Continued” campaign put patients and those they love at the center.
Each execution is viewed through the lens of living longer with the people you love, and continuing to do the things you love to do with them.
Tecentriq sales increased 55% in 2020 and the “To Be Continured” was a DTC Perspectives Awards 2021 Finalist.
>>Video “Dear Danny”
>>Print Campaign
